Evidence map›Paper›PMID 28456898›Full record

Trial reportPathology oncology research : POR2018

Predictive Value of Early Skin Rash in Cetuximab-Based Therapy of Advanced Biliary Tract Cancer.

Gábor Rubovszky, Barna Budai, Erna Ganofszky, Zsolt Horváth, Éva Juhos, Balázs Madaras, Tünde Nagy, Eszter Szabó, Tamás Pintér, Erika Tóth and 3 more

Abstract readClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Pathology oncology research : POR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Gábor RubovszkyDepartment of Medical Oncology and Clinical Pharmacology "B", National Institute of Oncology, Ráth Gy. u. 7-9, Budapest, 1122, Hungary. garub@oncol.hu.ORCID http://orcid.org/0000-0003-1723-5589
Barna BudaiDepartment of Molecular Immunology and Toxicology, National Institute of Oncology, Budapest, Hungary.
Erna GanofszkyDepartment of Medical Oncology and Clinical Pharmacology "B", National Institute of Oncology, Ráth Gy. u. 7-9, Budapest, 1122, Hungary.
Zsolt HorváthInstitute of Oncology, University of Debrecen, Debrecen, Hungary.
Éva JuhosDepartment of Medical Oncology and Clinical Pharmacology "B", National Institute of Oncology, Ráth Gy. u. 7-9, Budapest, 1122, Hungary.
Balázs MadarasDepartment of Medical Oncology and Clinical Pharmacology "B", National Institute of Oncology, Ráth Gy. u. 7-9, Budapest, 1122, Hungary.
Tünde NagyDepartment of Medical Oncology and Clinical Pharmacology "B", National Institute of Oncology, Ráth Gy. u. 7-9, Budapest, 1122, Hungary.
Eszter SzabóDepartment of Medical Oncology and Clinical Pharmacology "B", National Institute of Oncology, Ráth Gy. u. 7-9, Budapest, 1122, Hungary.
Tamás PintérDepartment of Medical Oncology and Clinical Pharmacology "B", National Institute of Oncology, Ráth Gy. u. 7-9, Budapest, 1122, Hungary.
Erika TóthSurgical and Molecular Tumor Pathology Centre, National Institute of Oncology, Budapest, Hungary.
Péter NagyDepartment of Molecular Immunology and Toxicology, National Institute of Oncology, Budapest, Hungary.
István LángDepartment of Medical Oncology and Clinical Pharmacology "B", National Institute of Oncology, Ráth Gy. u. 7-9, Budapest, 1122, Hungary.
Erika HitreDepartment of Medical Oncology and Clinical Pharmacology "B", National Institute of Oncology, Ráth Gy. u. 7-9, Budapest, 1122, Hungary.
National Institute of Oncology · HUUniversity of Debrecen · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Randomized trials in advanced biliary tract cancer (BTC) did not show benefit of cetuximab addition over chemotherapy. This is probably due to the lack of predictive biomarkers. The aim of this study was to explore possible predictive factors. Between 2009 and 2014, 57 patients were treated in 3-week cycles with cetuximab (250 mg/m

Indexed as

AdultAgedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsBiliary Tract NeoplasmsCapecitabineCetuximabDeoxycytidineDisease-Free SurvivalDrug EruptionsFemaleGemcitabineHumansKaplan-Meier EstimateMaleMiddle AgedAntineoplastic Agents, ImmunologicalCapecitabineCetuximabDeoxycytidineGemcitabineAcneiform rashCetuximabChemotherapyCholangiocarcinomaPredictive marker

Identifiers

PMID28456898
OpenAlexW2609776916

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.